Improving Cancer Prevention and Control Through Academic-local Public Health Department Partnerships

NCT ID: NCT06605196

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

364 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2028-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to understand how to leverage structures and processes of academic health department (AHD) partnerships to facilitate implementation of cancer related evidence-based programs and policies (EBPPs).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will conduct a group-randomized study (total N=28 AHD partnerships) to evaluate the effect of strategies to increase implementation of cancer control and prevention EBPPs by supporting AHD partnerships. Partnerships will be randomized 1:1 to either an active implementation arm in which they will receive tailored strategies based on prior knowledge of successful partnerships or to an existing set of resources for AHD partnerships. A mixed methods approach will be used to evaluate changes in AHD partnerships and understand how contextual factors may have impacted the AHD partnership's ability to support EBPP adoption.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Improving cancer prevention and control academic-local public health department partnerships

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Implementation Arm

The implementation arm will receive tailored, guided support to improve their AHD partnerships.

Group Type EXPERIMENTAL

Resources and guided facilitation

Intervention Type BEHAVIORAL

Participants in the intervention arm will participate in a planning period at the beginning of the intervention period to establish the goals for the partnership. The investigators will use the prioritized list of AHD partnership features developed in prior research to guide the initial planning period and then assist the partnership members to plan to implement the corresponding strategies focused on their areas of interest (e.g., developing collaborative projects, hiring faculty, staff, or students to conduct data analysis). The investigators will use telephone, email communication, and video conferencing to communicate with AHD partnerships, regularly assess progress towards goals, and adjust goals and strategies based on the progress. One additional in person visit to each AHD partnership in the intervention arm will be made in year 2 of implementation to review goals and progress and provide additional guidance and tailored support as needed.

Control Arm

The control arm will be referred to existing resources in the Learning Community but will not receive new resources or guided facilitation.

Group Type ACTIVE_COMPARATOR

Existing resources

Intervention Type BEHAVIORAL

Individuals will be referred to existing resources in the Learning Community.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Resources and guided facilitation

Participants in the intervention arm will participate in a planning period at the beginning of the intervention period to establish the goals for the partnership. The investigators will use the prioritized list of AHD partnership features developed in prior research to guide the initial planning period and then assist the partnership members to plan to implement the corresponding strategies focused on their areas of interest (e.g., developing collaborative projects, hiring faculty, staff, or students to conduct data analysis). The investigators will use telephone, email communication, and video conferencing to communicate with AHD partnerships, regularly assess progress towards goals, and adjust goals and strategies based on the progress. One additional in person visit to each AHD partnership in the intervention arm will be made in year 2 of implementation to review goals and progress and provide additional guidance and tailored support as needed.

Intervention Type BEHAVIORAL

Existing resources

Individuals will be referred to existing resources in the Learning Community.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Local health department practitioners who are involved in the implementation of cancer prevention and control programs within their communities and are engaged in an academic-health department partnership.
* Employees in academic settings currently partnering with local health departments. These partnerships could be located anywhere within the United States.

Exclusion Criteria

• Individuals under the age of 18 years old.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Washington University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephanie Mazzucca-Ragan

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Prevention Research Center at Washington University in St. Louis

St Louis, Missouri, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stephanie Mazzucca-Ragan

Role: CONTACT

Phone: 314-935-0117

Email: [email protected]

Mary Adams

Role: CONTACT

Phone: 314-935-0115

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Linda Dix

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Mazzucca-Ragan S, Allen P, Amos K, Barker AR, Brewer M, Erwin PC, Gannon J, Gao F, Jacob RR, Lengnick-Hall R, Brownson RC. Improving cancer prevention and control through implementing academic-local public health department partnerships - protocol for a cluster-randomized implementation trial using a positive deviance approach. Implement Sci Commun. 2025 Feb 24;6(1):20. doi: 10.1186/s43058-025-00706-z.

Reference Type DERIVED
PMID: 39994666 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://siteman.wustl.edu

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R37CA262011

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R37CA262011

Identifier Type: NIH

Identifier Source: org_study_id

View Link